A ₹11 IV Set Billed At ₹325 Lands On Someone's Health Insurance Claim

A Maharashtra Food and Drug Administration survey of hospital consumables has found an IV infusion set purchased at a trade price of ₹11.05 carrying a printed maximum retail price of ₹325, a markup of 2,841 per cent.

The survey covered syringes, catheters, oxygen masks, nebulisers and IV infusion sets used for patients admitted to private hospitals. A syringe procured at ₹6.75 carried an MRP of ₹57.20. A catheter bought at ₹29.41 carried an MRP of ₹310.

State FDA Commissioner Tukaram Mundhe submitted the findings to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority in a communication dated 10 August, seeking a review and regulatory action. His proposals include capping trade margins, introducing structured price monitoring, setting clear guidelines on how large the gap between trade procurement price and declared MRP should be, and bringing essential categories of medical devices within an effective price-regulation framework.

Mundhe said such devices are not elective purchases and that patients undergoing treatment cannot compare prices, seek alternatives or question a number printed on a box. He described the gap in information as a public health issue.

The regulatory position explains the spread. Under the Drugs (Prices Control) Order, 2013, the NPPA fixes ceiling prices for scheduled medicines and specified medical devices. Products outside the scheduled list are monitored rather than capped, with limits on annual MRP increases. Most hospital consumables sit outside that list.

Drug control authorities in Punjab, Rajasthan and Tamil Nadu have raised comparable concerns, and the NPPA is understood to be examining whether manufacturers and intermediaries are adding steep margins before products reach patients.

The finding is not new, and that is the most useful thing about it.

In 2018 the NPPA examined billing at four large private hospitals in Delhi and found margins of up to 1,737 per cent across drugs, consumables, devices and diagnostics. On disposable syringes it found 1,300 to 1,700 per cent. On IV infusion sets it found around 2,000 per cent. It also found that medicines, consumables and diagnostics together accounted for more than half the billed amount, against roughly 11 per cent each for room rent and procedures.

Eight years later a state regulator has examined the same category and found 2,841 per cent on the same product. The markup has widened since a national regulator documented it and published the finding.

That points at why Mundhe's proposal differs in kind from what came before. He is not asking for ceilings on individual products. He is asking for a cap on the trade margin, the permissible gap between what a hospital pays and what it prints.

The distinction matters because capping individual prices creates a substitution incentive. The 2018 study found exactly that, noting hospitals preferred prescribing non-scheduled medicines over scheduled ones because the margins were uncontrolled. Cap the IV set and the margin relocates to whatever is not yet on the list. A margin cap attacks the mechanism instead of the instance.

One caveat belongs alongside the percentage. The difference on that IV set is ₹314, which is dramatic proportionally and small against a bill running into lakhs. The stronger argument for materiality is the 2018 finding that these categories make up more than half the total.

For health insurers this is a claims problem before it is a pricing problem, and the distinction decides who ends up paying.

When a hospital bills a ₹11 consumable at ₹325, one of two things happens. The insurer pays it, in which case the cost enters the loss ratio and is recovered from the following year's premiums across the whole pool. Or the insurer disallows it, in which case the patient receives a bill they did not expect, for an item they had no opportunity to refuse while admitted. Neither outcome punishes the party that set the price.

That is the structural reason consumables have been among the most contested lines in Indian health claims for years. They are individually small, collectively large, clinically necessary and almost impossible for a patient to dispute after the fact.

What is striking is that insurers already hold the evidence. Any large health insurer processes enough claims to know that one hospital bills ₹325 for an item another bills ₹80 for. The analytics are not difficult and the data is sitting in claims systems already. What has been missing is a regulatory basis on which a variance of that size can be denied, because an MRP printed on a box has been, until now, a legally sufficient answer.

This is also precisely what IRDAI's proposed public insurance registry would surface. A consent-driven record covering the full claims lifecycle, at population scale, makes line-item price variation between hospitals visible in a way no single state survey can. Maharashtra examined a sample. A national claims registry would examine every admission.

The caution is that a trade margin cap alone will not reduce what patients pay. Hospitals earn on consumables because those margins are unregulated. Constrain them and the recovery moves to room rent, procedure charges and diagnostics, which insurers find considerably harder to benchmark. Unless the substitution is anticipated, the bill stays the same and only its composition changes.

For daily, sharp analysis of the biggest moves in the Indian business and startup ecosystem, follow StartupFox.